PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.12%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
21.56%
Positive gross profit growth while CRON.TO is negative. John Neff would see a clear operational edge over the competitor.
123.81%
Positive EBIT growth while CRON.TO is negative. John Neff might see a substantial edge in operational management.
123.81%
Positive operating income growth while CRON.TO is negative. John Neff might view this as a competitive edge in operations.
645.04%
Positive net income growth while CRON.TO is negative. John Neff might see a big relative performance advantage.
22200.00%
Positive EPS growth while CRON.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
22200.00%
Positive diluted EPS growth while CRON.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
5.52%
Slight or no buybacks while CRON.TO is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
6.15%
Diluted share count expanding well above CRON.TO's 0.55%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-170.95%
Negative OCF growth while CRON.TO is at 22.54%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-106.82%
Negative FCF growth while CRON.TO is at 21.76%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
656.29%
5Y revenue/share CAGR similar to CRON.TO's 622.14%. Walter Schloss might see both companies benefiting from the same mid-term trends.
17.13%
3Y revenue/share CAGR under 50% of CRON.TO's 100.34%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-267.86%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-478.36%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-28.16%
Negative 3Y OCF/share CAGR while CRON.TO stands at 38.43%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
440.92%
10Y net income/share CAGR of 440.92% while CRON.TO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
122.39%
Positive 5Y CAGR while CRON.TO is negative. John Neff might view this as a strong mid-term relative advantage.
122.65%
Positive short-term CAGR while CRON.TO is negative. John Neff would see a clear advantage in near-term profit trajectory.
6526.78%
Equity/share CAGR of 6526.78% while CRON.TO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
522.42%
5Y equity/share CAGR at 50-75% of CRON.TO's 702.14%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
56.04%
Positive short-term equity growth while CRON.TO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.73%
AR growth well above CRON.TO's 5.73%. Michael Burry fears inflated revenue or higher default risk in the near future.
17.28%
We show growth while CRON.TO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
0.97%
Positive asset growth while CRON.TO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-1.25%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-8.37%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-68.16%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
19.59%
SG&A growth well above CRON.TO's 8.54%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.